ASH 2024: New Treatments in Trial Pipeline Show Promising Survival Rates in R/R Multiple Myeloma

by | Dec 9, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Robert Rifkin, MD, FACP, discusses multiple abstracts featuring drugs demonstrating efficacy in patients with relapsed/refractory multiple myeloma.
Read More

Submit a Comment